Tags

Type your tag names separated by a space and hit enter

Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
Vaccine. 2013 Dec 02; 31(49):5798-805.V

Abstract

Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) is a rare and serious adverse event of the yellow fever (YF) vaccine that mimics wild-type YF. Research shows there may be an increased risk of YEL-AVD among the elderly population (≥ 60-65 years old), however this research has yet to be accumulated and reviewed in order to make policy recommendations to countries currently administering the YF vaccine. This paper systematically reviewed all information available on YEL-AVD to determine if there is an increased risk among the elderly, for both travelers and endemic populations. Age-specific reporting rates (RRs) were re-calculated from the literature using the Brighton Collaboration case definition for YEL-AVD and were then analyzed to determine if there was a significant difference between the RRs of younger and older age groups. Two out of the five studies found a significantly higher rate of YEL-AVD among the elderly population. Our findings suggest unexposed elders may be at an increased risk of developing YEF-AVD, however the evidence remains limited. Therefore, our findings for YF vaccination of elderly populations support the recommendations made by the Strategic Advisory Group of Experts (SAGE) in their April 2013 meeting, mainly vaccination of the elderly should be based on a careful risk-benefit analysis.

Authors+Show Affiliations

University of Saskatchewan, Saskatoon, Saskatchewan S7 N 5A2, Canada. Electronic address: err593@mail.usask.ca.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review
Systematic Review

Language

eng

PubMed ID

24079979

Citation

Rafferty, Ellen, et al. "Risk of Yellow Fever Vaccine-associated Viscerotropic Disease Among the Elderly: a Systematic Review." Vaccine, vol. 31, no. 49, 2013, pp. 5798-805.
Rafferty E, Duclos P, Yactayo S, et al. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review. Vaccine. 2013;31(49):5798-805.
Rafferty, E., Duclos, P., Yactayo, S., & Schuster, M. (2013). Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review. Vaccine, 31(49), 5798-805. https://doi.org/10.1016/j.vaccine.2013.09.030
Rafferty E, et al. Risk of Yellow Fever Vaccine-associated Viscerotropic Disease Among the Elderly: a Systematic Review. Vaccine. 2013 Dec 2;31(49):5798-805. PubMed PMID: 24079979.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review. AU - Rafferty,Ellen, AU - Duclos,Philippe, AU - Yactayo,Sergio, AU - Schuster,Melanie, Y1 - 2013/09/27/ PY - 2013/08/15/received PY - 2013/09/12/revised PY - 2013/09/16/accepted PY - 2013/10/2/entrez PY - 2013/10/2/pubmed PY - 2014/6/3/medline KW - AEFI KW - AVD KW - Adverse event KW - Elderly KW - RR KW - RRR KW - Viscerotropic disease KW - YEL-AVD KW - YF KW - YFWG KW - Yellow fever KW - Yellow fever vaccine KW - adverse events following immunization KW - reporting rate ratios KW - reporting rates KW - serious AEFI KW - serious adverse events following immunization KW - viscerotropic disease KW - yellow fever KW - yellow fever vaccine safety working group KW - yellow fever vaccine-associated viscerotropic disease SP - 5798 EP - 805 JF - Vaccine JO - Vaccine VL - 31 IS - 49 N2 - Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) is a rare and serious adverse event of the yellow fever (YF) vaccine that mimics wild-type YF. Research shows there may be an increased risk of YEL-AVD among the elderly population (≥ 60-65 years old), however this research has yet to be accumulated and reviewed in order to make policy recommendations to countries currently administering the YF vaccine. This paper systematically reviewed all information available on YEL-AVD to determine if there is an increased risk among the elderly, for both travelers and endemic populations. Age-specific reporting rates (RRs) were re-calculated from the literature using the Brighton Collaboration case definition for YEL-AVD and were then analyzed to determine if there was a significant difference between the RRs of younger and older age groups. Two out of the five studies found a significantly higher rate of YEL-AVD among the elderly population. Our findings suggest unexposed elders may be at an increased risk of developing YEF-AVD, however the evidence remains limited. Therefore, our findings for YF vaccination of elderly populations support the recommendations made by the Strategic Advisory Group of Experts (SAGE) in their April 2013 meeting, mainly vaccination of the elderly should be based on a careful risk-benefit analysis. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/24079979/Risk_of_yellow_fever_vaccine_associated_viscerotropic_disease_among_the_elderly:_a_systematic_review_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(13)01271-1 DB - PRIME DP - Unbound Medicine ER -